funding
AureoGen
has to date raised approximately $8.3 million from the following
sources:
$200,000.
Start-up funding from the Michigan Economic Development Corporation
(MEDC), September 4th 2003.
$1,994,476.
A convertible loan from the Michigan Tri-Technology Corridor (MTTC),
for development of genetic tools and methodologies for efficient
engineering of cyclic peptide producing organisms, June 29th, 2004.
$162,982.
Phase I SBIR grant from the National Institutes of Health (NIH), for
a project entitled Novel Antifungals by Engineering a NRPS gene,
September 17th, 2004.
$1,450,508.
Three year grant from the National Institutes of Standards and
Technology, Advanced Technology Program (NIST/ATP), for a project
entitled “A Genetic Engineering Technology Platform for Production
of Novel Cyclic Peptide-Based Drugs, September 28th, 2004.
$225,000.
Investment/convertible loan from the Western Michigan University
(WMU) Bioscience Research and Commercialization Center (BRCC), April
1, 2005.
$1,978,701.
Three year SBIR grant from the National Institutes of Health (NIH),
for Phase II of the project Novel Antifungals by Engineering a NRPS
gene, May 15th, 2006.
$381,116.
SBIR Phase I grant entitled, A Bacitracin derivative for systemic
use, awarded June 22, 2007
$600,000.
SBIR
Phase I ATP grant (two years) entitled, Generation of novel HCV
drugs through engineering of the cssA gene, awarded March 27, 2008.
$286,746.
SBIR
Phase I grant entitled, Generation of novel drugs against drug
resistant bacteria through engineering of the empedopeptin
biosynthesis gene, awarded June 13, 2008
$244,479.
Qualifying Therapeutic Discovery Project award, October 29, 2010
$487,411.
Competitive renewal of NIH Phase II SBIR grant for the project Novel
Antifungals by Engineering a NRPS gene, Feb 11th, 2011.
$340,000.
Investment/convertible loan from the Western Michigan University
(WMU) Bioscience Research and Commercialization Center (BRCC),
January 31, 2014.
The
company is actively pursuing additional funding from both public and
private sources.